Business Standard

Dr Reddy's launches cancer drug Abiraterone Acetate in US market

The drug is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson

Dr Reddy's
Premium

The drug, which is used in cancer treatment, is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson.

BS Reporter Hyderabad
Dr Reddy's Laboratories Limited today announced the launch of Abiraterone Acetate Tablets in the US market, following approval from the US Food and Drug Administration (USFDA). 

The drug, which is used in cancer treatment, is a therapeutic equivalent generic version of Zytiga owned by Johnson & Johnson.

Abiraterone Acetate is a significant launch for the company, as the Zytiga brand and generic market had US sales of approximately $454 million for the most recent twelve months ending in March 2020 according to IQVIA Health.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in